Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. The company is headquartered in Madison, Wisconsin. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.
How did ARAY's recent EPS compare to expectations?
The most recent EPS for Accuray Inc is $-0.11, not beating expectations of $-0.11.
How did Accuray Inc ARAY's revenue perform in the last quarter?
Accuray Inc revenue for the last quarter is $-0.11
What is the revenue estimate for Accuray Inc?
According to 4 of Wall street analyst, the revenue estimate of Accuray Inc range from $143.75M to $130.72M
What's the earning quality score for Accuray Inc?
Accuray Inc has a earning quality score of B+/55.321095. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Accuray Inc report earnings?
Accuray Inc next earnings report is expected in 2026-05-05
What are Accuray Inc's expected earnings?
Accuray Inc expected earnings is $102.86M, according to wall-street analysts.
Did Accuray Inc beat earnings expectations?
Accuray Inc recent earnings of $102.24M does not beat expectations.